North America Kidney Transplant Market will increase by around US$ 14.76 Billion by 2027. A kidney transplant is a surgical surgery that a healthy kidney is used to replace a damaged or sick kidney donated by another person. The goal of the transplant is to improve or restore the function of the recipient’s kidneys, allowing them to live healthier lives with less dependence on dialysis. The success of a kidney transplant is dependent on various factors, including donor-recipient compatibility, good post-operative care, and the recipient’s overall health.

In the United States and Canada, there is a large population of individuals with kidney disease, and a significant portion of these individuals require dialysis or a kidney transplant to manage their condition. A kidney transplant can offer these individuals a better quality of life, increased lifespan, and improved health outcomes compared to relying on dialysis alone. Additionally, the availability of advanced medical technology and skilled medical professionals in North American countries make kidney transplantation a safe and effective option for eligible patients. According to our study, the number of kidney transplants in 2022 will be 30.67 thousand, rising to 39.44 thousand by 2027.

North America Kidney Transplant Market will grow at a CAGR of 5.37% during the Forecast Period
Growing demand for kidney transplantation is also one of the key drivers driving expansion potential in the North American sector in the next years. A kidney transplant is reliant on a variety of variables and circumstances. These disorders include renal failure caused by several factors, such as acute dehydration and kidney damage.
The unexpected spike in COVID-19 cases is also expected to raise demand for PPE kits and gloves in North America. Governments from all across the world have taken several initiatives to combat the spread of the new coronavirus. However, the installation of the lockdown has caused global disruptions in the manufacture, distribution, and delivery of medical supplies. Furthermore, health and clinic centers have declined drastically in recent years in order to preserve social distance. These issues will most likely restrict development opportunities in the kidney transplant industry in the next few years.

According to the (OPTN) Organ Procurement and Transplantation Network, 42,887 organ transplants will be done in the United States in 2022, a 3.7% increase over 2021. In addition, for the first time, over 25,000 kidney transplants were done in the United States. The number of 25,498 represented a 3.4 percent increase over 2021. Furthermore, factors such as increased public awareness of organ donation, the development of healthcare infrastructure, and the implementation of favorable reimbursement policies will contribute to the market’s growth.

However, problems such as high transplantation costs and lengthy wait times are important impediments to the expansion of the North American kidney transplant industry. Nevertheless, the report shows that the North American kidney transplant market was at US$ 11.36 Billion in 2022.

By Region: The United States captured the Highest Market Share
The North American Kidney Transplant Market is divided into; the United States, Mexico, and Canada. In the United States and Canada, there is a large population of individuals with kidney disease, and a significant portion of these individuals require dialysis or a kidney transplant to manage their condition. A kidney transplant can offer these individuals a better quality of life, increased lifespan, and improved health outcomes compared to relying on dialysis alone. Additionally, the availability of advanced medical technology and skilled medical professionals in North American countries make kidney transplantation a safe and effective option for eligible patients.

By Type: The Living Donor Transplant Market will rise in the Foreseeable Years
Based on types, the North American market is segmented into; deceased donor transplants and living donor transplants. The living donor transplant segment is forecasted to grow at a significant rate. As the living donor transplant takes place sooner, the kidney has fewer chances of rejection and lasts longer (15-20 years on average).

By Drugs: The Calcineurin Inhibitors Revenue will grow due to Advancement and Technology in the Healthcare Industry
The Drugs categorizes into; calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and antibodies. Calcineurin inhibitors are a class of immunosuppressive drugs used in the management of organ transplantation, including kidney transplantation, in North American countries. These drugs help prevent the rejection of the transplanted organ by suppressing the immune system’s response to the foreign tissue. The two most commonly used calcineurin inhibitors in North America are Cyclosporine and Tacrolimus. Both drugs are highly effective in preventing rejection, but they have different side-effect profiles and dosing requirements. These drugs are administered orally or intravenously and are typically prescribed in combination with other immunosuppressive medications to provide a more complete and effective immunosuppression regimen for transplant patients. Patients on the waiting list vs. Liver organ transplants conducted in 2021 were 90,483 out of 25,498 transplants performed, According to the Organ Procurement and Transplantation Network Data.

Renub Research report titled “North America Kidney Transplant Market & Number, Forecast by Types (Deceased donor transplant, and living donor transplant), Drugs (Calcineurin inhibitors, Antiproliferative agents, mTor inhibitor, Steroids, and Antibodies), Region (United States, Canada, and Mexico)” studies the North America Kidney Transplant Industry.

Type – Kidney Transplant Market breakup from 3 viewpoints:

  1. Deceased Donor Transplant
  2. Living Donor Transplant

Drugs – Kidney Transplant Market breakup from 4 viewpoints

  1. Calcineurin inhibitors
  2. Antiproliferative agents
  3. mTor inhibitor
  4. Steroids
  5. Antibodies

Region – Kidney Transplant Market breakup from 3 Regions:

  1. United States
  2. Canada
  3. Mexico